hypoglycemic agent


Also found in: Dictionary, Thesaurus, Wikipedia.

hy·po·gly·ce·mic a·gent

(hī'pō-glī-sē'mik ā'jĕnt)
Oral medications used in the management of Type 2 diabetes mellitus, but ineffective in Type 1 diabetes.
References in periodicals archive ?
All subjects maintained their usual diabetes therapy which consisted of the oral hypoglycemic agents sulfonylurea and/or metformin.
Dhulkotia JS, Ola B, Fraser R, Farrell Z Oral hypoglycemic agents us insulin in management of gestational diabetes: a systematic review and metaanalysis.
DISCUSSION: Oral hypoglycemic agents involved in drug induced hypoglycemic coma (DIHC) are: gliclazide, glibenclamide, metformin, repaglinide, glimepiride and buformin.
One study showed that, among diabetic patients whose doses of oral hypoglycemic agents (OHA) were modified during Ramadan, 58% had changed the timings of the administration of their medications [8].
potent hypoglycemic agent in streptozotocin (STZ)-induced diabetic rats from Swertia japonica.
The major classes of synthetic oral hypoglycemic agents currently available for the management and/or control of adult-onset, NIDDM, type-2 diabetes mellitus include the sulphonylureas, biguanides, thiazolidinediones, alpha-glucosidase inhibitors, and so forth.
Type 2 diabetes was defined in terms of treatment by diet or with oral hypoglycemic agents, alone or with insulin.
Schucker said she has found particularly reassuring a study in which 404 gestational diabetic women were randomized to insulin or the second-generation oral hypoglycemic agent. All major maternal and neonatal outcomes were comparable in the two groups (N.
Drug therapy may consist of an oral hypoglycemic agent, insulin, or a combination of both.
One-quarter of patients were treated by diet alone, 12% with an oral hypoglycemic agent alone, 37% with an oral hypoglycemic agent plus insulin, and a further 28% were using only insulin.
Senior Writer Thiazolidinedione Combinations Used to Treat Diabetes TZD, plus oral hypoglycemic agent 48% TZD, plus oral hypoglycemic agent, plus insulin 36% TZD, plus insulin 10% TZD only 6% Note: Based on data from 22,709 patients who had taken TZDs to treat type 2 diabetes.
They included only trials in which a hypoglycemic agent was compared with either placebo or with another active drug in combination with metformin for at least 16 weeks.